Benitec Biopharma Price to Book Ratio 2014-2022 | BNTC

Historical price to book ratio values for Benitec Biopharma (BNTC) over the last 10 years. The current price to book ratio for Benitec Biopharma as of February 03, 2023 is 0.39.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Benitec Biopharma Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-02-03 0.22 0.00
2022-09-30 0.37 $113.24 0.00
2022-06-30 1.16 $70.54 0.02
2022-03-31 2.34 $183.41 0.01
2021-12-31 2.62 $264.29 0.01
2021-09-30 3.57 $377.44 0.01
2021-06-30 4.25 $489.72 0.01
2021-03-31 5.17 $455.42 0.01
2020-12-31 3.00 $644.27 0.00
2020-09-30 6.28 $1,396.39 0.00
2020-06-30 7.91 $2,047.60 0.00
2020-03-31 3.93 0.00
2019-09-30 7.11 0.00
2017-09-30 21.70 $21.68 1.00
2016-09-30 14.00 $30.63 0.46
2016-06-30 12.68 0.00
2016-03-31 17.10 0.00
2015-12-31 40.20 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00